Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations

Clinical Infectious Diseases

Volumn 68, Issue 3, 2019, Pages 519-524

  Pogue, Jason M ^a,b   Bonomo, Robert A ^c,d,e   Kaye, Keith S ^f  

^a SINAI GRACE HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

antimicrobial stewardship.; carbapenem resistant Enterobacteriaceae; ceftazidime avibactam; Klebsiella pneumoniae carbapenemase; meropenem vaborbactam

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; COLISTIN; MEROPENEM PLUS VABORBACTAM; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; BORONIC ACID DERIVATIVE; CEFTAZIDIME; MEROPENEM; MEROPENEM AND VABORBACTAM; SINGLE HETEROCYCLIC RINGS;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL STEWARDSHIP; ARTICLE; CARBAPENEM RESISTANCE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; DISEASE MANAGEMENT; DRUG COMBINATION; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; BORONIC ACIDS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; DISEASE MANAGEMENT; DRUG COMBINATIONS; ENTEROBACTERIACEAE INFECTIONS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MEROPENEM;

EID: 85060161135     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy576     Document Type: Article

References (32)

1. Morrill HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis 2015; 2:ofv050.
2. Satlin MJ, Chen L, Patel G, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother 2017; 61 pii:e02349-16.
3. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:1151-61.
4. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13:785-96.
5. Albiger B, Glasner C, Struelens M, Grundmann H, Monnet D; The European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Carbapenemase-producine Enterobacteriaceae in Europe: assessment by national experts in 38 countries, May 2015. Euro Surveill 2015;20: pii:30062.
6. Rahman M, Shukla SK, Prasad KN, et al. Prevalence and molecular characterisation of New Delhi metallo-lactamases NDM-1, NDM-5, NDM-6 and NDM-7 in multidrug-resistant Enterobacteriaceae from India. Int J Antimicrob Agents 2014; 44:30-7.
7. Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. Ceftazidimeavibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011-2013) and characterization of -lactamase producing strains. Antimicrob Agents Chemother 2015; 59:3509-17
8. Haidar G, Clancy CJ, Chen L, et al. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61. pii:e00642-17.
9. Shen Z, Ding B, Ye M, et al. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother 2017; 72:1930-6.
10. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67:1597-606.
11. Akta Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with -lactams against gram-negative bacteria, including OXA-48 -lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012; 39:86-9.
12. Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother 2017; 62. pii:e01904-17.
13. Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 2017; 61. pii:e01443-17.
14. Livermore DM, Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate -lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother 2013; 68:1825-31.
15. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 2017; 61. pii:e00883-17.
16. van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2018; 66:163-71.
17. Kaye KS, Vazquez J, Mathers A, et al. Clinical outcomes of serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) in TANGO II, a phase 3, randomized, multi-national, open-label trial of meropenem-vaborbactam versus best available therapy [abstract 1862]. In: IDWeek, San Diego, CA, 2017.
18. Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 2015; 59:6605-7.
19. Humphries RM, Hemarajata P. Resistance to ceftazidime-avibactam in Klebsiella pneumoniae due to porin mutations and the increased expression of KPC-3. Antimicrob Agents Chemother 2017; 61. pii:e00537-17.
20. Livermore DM, Warner M, Jamrozy D, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 2015; 59:5324-30.
21. Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV -lactamases with single amino acid substitutions in the -loop. J Antimicrob Chemother 2015; 70:2279-86.
22. Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 2016; 63:1615-8.
23. Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum -lactamases. Antimicrob Agents Chemother 2017; 61. pii:e02534-16.
24. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother 2017; 61. pii:e00079-17.
25. Lomovskaya O, Castanheira M, Vazquez J, et al. Assessment of MIC increases with meropenem-vaborbactam and ceftaizdime-avibactam in TANGO II (a phase 3 study of the treatment of CRE infections [abstract 1874]. In: IDWeek. San Diego, CA, 2017.
26. Giddins MJ, Macesic N, Annavajhala MK, et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother 2018; 62. pii:e02101-17.
27. Sabet M, Tarazi Z, Rubio-Aparicio D, et al. Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow-fiber model. Antimicrob Agents Chemother 2018; 62. pii:e01969-17.
28. Sun D, Rubio-Aparicio D, Nelson K, Dudley MN, Lomovskaya O. Meropenemvaborbactam resistance selection, resistance prevention, and molecular mechanisms in mutants of KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2017; 61. pii:e01694-17.
29. Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN. Pharmacodynamics of vaborbactam when administered in combination with meropenem. In: American Society for Microbiology Microbe meeting, New Orleans, LA, 2017.
30. Wang X, Zhang F, Zhao C, et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother 2014; 58:1774-8.
31. Mojica MF, Ouellette CP, Leber A, et al. Successful treatment of bloodstream infection due to metallo-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. Antimicrob Agents Chemother 2016; 60:5130-4.
32. Shaw E, Rombauts A, Tubau F, et al. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 2017; 73:1104-6.